{"filing":{"accession_number":"0001640266-26-000007","cik":"0001640266","ticker":"VYGR","company_name":"Voyager Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"vygr-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1640266/000164026626000007/vygr-20260806.htm"},"events":[{"id":25924,"run_id":23538,"accession_number":"0001640266-26-000007","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Voyager's second quarter 2026 financial results, including collaboration revenue ($3.2M), R\u0026D expenses ($22.0M), G\u0026A expenses ($7.5M), net loss ($24.5M), and cash position ($148.8M with runway into 2028). The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly states the company \"announced second quarter 2026 financial results and corporate updates.\" The disclosure includes both financial statements (consolidated balance sheet and statement of operations) and material operational milestones (VY7523 and VY1706 clinical data expected Q4 2026).","company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26865,"accession_number":"0001640266-26-000007","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Voyager's second quarter 2026 financial results, including collaboration revenue ($3.2M), R\u0026D expenses ($22.0M), G\u0026A expenses ($7.5M), net loss ($24.5M), and cash position ($148.8M with runway into 2028). The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly states the company \"announced second quarter 2026 financial results and corporate updates.\" The disclosure includes both financial statements (consolidated balance sheet and statement of operations) and material operational milestones (VY7523 and VY1706 clinical data expected Q4 2026).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:47:14.112102+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26865,"accession_number":"0001640266-26-000007","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Voyager's second quarter 2026 financial results, including collaboration revenue ($3.2M), R\u0026D expenses ($22.0M), G\u0026A expenses ($7.5M), net loss ($24.5M), and cash position ($148.8M with runway into 2028). The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly states the company \"announced second quarter 2026 financial results and corporate updates.\" The disclosure includes both financial statements (consolidated balance sheet and statement of operations) and material operational milestones (VY7523 and VY1706 clinical data expected Q4 2026).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:47:14.112102+00:00","company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","filing_date":"2026-08-06"}]}